Dr.
Charles Lazelle Sawyers
Memorial Sloan Kettering Cancer Center
Oncologist; Physician; Research institution scientist
Area
Biological Sciences
Specialty
Medical Sciences
Elected
2014
Sawyers studies mechanisms of cancer drug resistance with an eye toward developing novel therapies. He co-discovered the antiandrogen drug enzalutamide that was approved by the FDA in 2012 for treatment of advanced prostate cancer. He shared the 2009 Lasker~DeBakey Clinical Medical Research Award for the development of the ABL kinase inhibitor imatinib for patients with chronic myeloid leukemia and the second generation ABL inhibitor dasatinib to overcome imatinib resistance. Sawyers has served at the Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center since 2006, where he is also an Investigator of the Howard Hughes Medical Institute. He is a member of the National Academy of Sciences and the Institute of Medicine and President of the American Association for Cancer Research. He was appointed to the National Cancer Advisory Board by President Obama and serves on the Board of Directors of Novartis.
Last Updated